CancerDrs Find care

Thyroid Cancer clinical trials in New York

21 actively recruiting thyroid cancer trials at 15 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New York:
  • Local Institution - 2117 — New York, New York
  • Local Institution - 1002 — New York, New York
  • Local Institution - 2102 — New York, New York
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…

Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in New York:
  • Clinical Trial Site — New York, New York
  • Clinical Trial Site — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The resear…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06007924
Sites in New York:
  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) — Commack, New York
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Rockville Centre, New York
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer
NCT ID: NCT05538130
Sites in New York:
  • Optum Medical Care, PC — Brewster, New York
  • MSK Commack. — Commack, New York
  • MSK Westchester. — Harrison, New York
  • Laura & Isaac Perlmutter Cancer Center - NYU ACC — New York, New York
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in New York:
  • MSK David H. Koch Center for Cancer Care — New York, New York
  • Memorial Sloan Kettering Cancer Center 53rd street — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1 Recruiting Industry

SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Sponsor: Solve Therapeutics
NCT ID: NCT06771219
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1 Recruiting Academic/Other

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive io…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03647358
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1 Recruiting Academic/Other

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who p…

Sponsor: Brian Henick, MD
NCT ID: NCT06673329
Sites in New York:
  • Columbia University Irving Medical Center — New York, New York
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New York:
  • Elmhurst Hospital Center — Elmhurst, New York
  • Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
  • Glens Falls Hospital — Glens Falls, New York
  • Queens Hospital Center — Jamaica, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in New York:
  • Montefiore Medical Center-Einstein Campus — The Bronx, New York
  • Montefiore Medical Center-Weiler Hospital — The Bronx, New York
  • Children's Hospital at Montefiore — The Bronx, New York
  • Montefiore Medical Center - Moses Campus — The Bronx, New York
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in New York:
  • C.R. Wood Cancer Center, Glens Falls Hospital — Glens Falls, New York
  • Faxton St. Luke's Healthcare, Mohawk Valley — Utica, New York
NA Recruiting Academic/Other

A Study of Multiparametric Ultrasound Imaging Methods

The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The r…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07270237
Sites in New York:
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) — Commack, New York
  • Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
  • Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York
NA Recruiting Industry

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyr…

Sponsor: Pulse Biosciences, Inc.
NCT ID: NCT07287176
Sites in New York:
  • NYU Langone Health — New York, New York
  • Weill Cornell Medicine — New York, New York
Recruiting Academic/Other

New MRI Biomarkers in Head and Neck Cancers

Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood vessels, or tumors easier to see. Diffusio…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03483337
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
Recruiting Academic/Other

Environmental Factors and Thyroid Cancer

Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using high quality diagnostic imaging explains only about 50% of thi…

Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT05172921
Sites in New York:
  • Icahn School of Medicine at Mount Sinai — New York, New York
NA Recruiting Academic/Other

Radiofrequency Ablation Study in LatinX Patients

Benign thyroid nodules can still create cosmetic, compressive, or hormonal issues for patients. In the past, surgery was typically used to treat thyroid nodules causing the above issues through partial or complete thyroidectomy. More recen…

Sponsor: Northwell Health
NCT ID: NCT05903196
Sites in New York:
  • Northwell Health Physician Partners — New York, New York
NA Recruiting Academic/Other

Decision Aid and Thyroid Nodules Management

Patients with small favorable malignant or indeterminate thyroid nodules will receive information about management of thyroid nodules. Participants will be asked to complete brief surveys at the time of enrollment, shortly after the consul…

Sponsor: Stony Brook University
NCT ID: NCT05264857
Sites in New York:
  • Stony Brook University Cancer Center — Stony Brook, New York
Recruiting Academic/Other

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05733013
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
Recruiting Academic/Other

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programe…

Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT04615988
Sites in New York:
  • Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center — New York, New York

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20